Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
about
Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant TumoursEGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastomaMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateTargeted molecular therapies against epidermal growth factor receptor: past experiences and challengesNovel delivery strategies for glioblastomaPI3K/PTEN signaling in angiogenesis and tumorigenesisInteractions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapyEGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Effect of lipid mimetics of GM3 and lyso-GM3 dimer on EGF receptor tyrosine kinase and EGF-induced signal transduction.Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor modelsMolecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastomaPilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesExperimental approaches for the treatment of malignant gliomas.Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.mTOR signaling in glioblastoma: lessons learned from bench to bedside.Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications.Glial progenitors as targets for transformation in glioma.Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cellsThe challenges and the promise of molecular targeted therapy in malignant gliomas.Innovative Therapies against Human Glioblastoma MultiformeCombined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo.Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.Investigating mammalian target of rapamycin inhibitors for their anticancer properties.Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsTargeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.Inhibiting kinases in malignant gliomas.
P2860
Q21284986-4EBF659D-B1DF-422A-9721-DE3572ECEA1FQ24338526-01B85A08-A34A-4134-9A16-8A2F5CB3FA10Q26822717-681D5D7E-19DE-4130-BEAA-1717B30F3AF3Q26862516-3C0240A6-BEE2-43C1-A86F-AA7E202E6B92Q27006099-3AAB323B-317D-418A-B7C0-77100E602800Q28383083-C9DE94C3-4971-47AF-B3BF-1AA4E2332CADQ30437740-9F22A54E-AE0B-4722-9B5D-F958C2EECCBBQ30456087-AA46526A-C56C-4643-80F2-4CF4EDD6CB39Q33307091-8AB4AD0B-2C4F-438B-A959-39DABED540E8Q33393707-DC98F9BB-C940-45DD-9162-63B22401FAFAQ33578960-A900A4AA-2F11-4F76-BE7A-BD810D8191EAQ33644407-3E9127EA-9738-4699-8703-1A8450F9ABEBQ33747609-8179EE15-B0B5-46AA-AEEA-52839A18E1FEQ33771160-432E5596-AFDA-4B96-A860-0306EA67F848Q33858387-3FFDCE78-937B-4494-80A5-2D12DDF5E096Q33872371-CD92259D-3499-4CC6-806C-E2CF7F54EA7EQ33925544-6BDCE07F-1AB6-4A93-A31B-374BE221A2CEQ34127138-7060D7D6-C9C0-41D6-BD7E-1A96E67B0D9AQ34132781-2B1366A7-F7BF-45F9-8AC0-19C8468768D8Q34133033-1D95ABCF-D338-43AC-8ED2-565720B1D30DQ34196216-743852E0-1310-4A8F-AA4A-DDC89F8A4812Q34363435-E2C1CE6C-F08F-474D-9CFB-0D5703E244CFQ34447846-03EDF372-594C-4BAC-A5BE-4F5908A2F2F6Q34480689-B772ECA6-B487-432B-B2B7-4F7057D18884Q34610495-867B5690-3AD5-4947-AE35-88D0BFC3D0C8Q34735661-919655B8-753A-4873-9392-8CD1E4AFA832Q34966112-240CFBBC-EFA4-4D3D-AE15-A7BEDA3E2317Q35214534-126F0742-AC39-44DD-870F-E71655E5E33EQ35374492-CAECDF86-4C12-4081-A514-19512D911076Q35534349-F63B2FCA-8518-4682-BD93-471371AA7267Q35542196-BBB25E2A-97DD-419D-90D3-3A88B16115DCQ35864082-24C74809-83AF-479D-B0B7-D1695B05803CQ35914525-EC53EEED-7F52-422C-B58F-858E6D3C3345Q36499234-2EAF1DD3-25D7-4B04-BA3A-CA73EFF4E5F2Q36544472-75DAA701-D7CE-4D4E-A391-BE5505760D0BQ36600294-6043EE89-BE75-4886-93AF-330995531494Q36668246-16775909-696C-4BD0-984E-27ED2D32386DQ36740744-D3749FC4-C749-4D1C-B88D-079DBF3295B4Q36742629-BFDBC2AA-650F-4460-85BA-2BB8F727F362Q36764876-CB667FAC-42B8-4934-AAC8-4EB0B391279B
P2860
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
@ast
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
@en
type
label
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
@ast
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
@en
prefLabel
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
@ast
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
@en
P2093
P50
P1476
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
@en
P2093
Alan J Swaisland
James E Herndon
James J Vredenburgh
James M Provenzale
Jeannette M Dowell
Jennifer A Quinn
Jeremy N Rich
John H Sampson
Judith S Ochs
Peggy Lyons
P304
P356
10.1158/1078-0432.CCR-05-2215
P407
P433
P50
P577
2006-02-01T00:00:00Z